Affiliation:
1. Jiangyin People's Hospital
2. Nanjing Medical University
Abstract
Abstract
Background
N6-methyladenosine (m6A) and 5-methylcytosine (m5C) RNA modifications have garnered significant attention in the field of epigenetic research due to their close association with human cancers. This study we focus on elucidating the expression patterns of m6A/m5C-related long non-coding RNAs (lncRNAs) in esophageal squamous cell carcinoma (ESCC) and assessing their prognostic significance and therapeutic potential.
Methods
Transcriptomic profiles of ESCC were derived from public resources. m6A/m5C-related lncRNAs were obtained from TCGA using Spearman’s correlations analysis. The m6A/m5C-lncRNAs prognostic signature was selected to construct a RiskScore model for survival prediction, and their correlation with the immune microenvironment and immunotherapy response was analyzed.
Results
A total of 606 m6A/m5C-lncRNAs were screened, and ESCC cases in the TCGA cohort were stratified into three clusters, which showed significantly distinct in various clinical features and immune landscapes. A RiskScore model comprising ten m6A/m5C-lncRNAs prognostic signature were constructed and displayed good independent prediction ability in validation datasets. Patients in the low-RiskScore group had a better prognosis, a higher abundance of immune cells (CD4 + T cell, CD4 + naive T cell, class-switched memory B cell, and Treg), and enhanced expression of most immune checkpoint genes. Importantly, patients with low-RiskScore were more cline benefit from immune checkpoint inhibitor treatment (P < 0.05).
Conclusion
Our findings underscore the potential of RiskScore system comprising ten m6A/m5C-related lncRNAs as effective biomarkers for predicting survival outcomes, characterizing the immune landscape, and assessing response to immunotherapy in ESCC.
Publisher
Research Square Platform LLC
Reference44 articles.
1. The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020;Morgan E;Gastroenterology,2022
2. Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M et al: Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up: Ann Oncol. 2022;33(10):992–1004. doi: 10.1016/j.annonc.2022.07.003. Epub 2022 Jul 29.; 2022.
3. Role of RNA modifications in cancer;Barbieri I;Nat Rev Cancer,2020
4. 5-methylcytosine promotes mRNA export - NSUN2 as the methyltransferase and ALYREF as an m(5)C reader;Yang X;Cell Res,2017
5. Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells;Han D;Nature,2019